StevenRYtterbergMD
Rheumatology • Rochester, MNMyositis, Rheumatoid Arthritis & Related, Vasculitis
Associate Professor, Internal Medicine, Mayo Medical School
Dr. Ytterberg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
200 1st St Sw
Rochester, MN 55905Phone+1 507-284-2511- Is this information wrong?
Education & Training
University of Michigan Health SystemFellowship, Rheumatology, 1980 - 1983
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 1976 - 1980- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1976
Certifications & Licensure
MN State Medical License 1984 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- Fellow (FACR) American College of Rheumatology
Clinical Trials
- Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) Start of enrollment: 2006 Apr 01
- Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis Start of enrollment: 2006 Apr 01
- Determining Disease Activity Biomarkers in Individuals With Polyarteritis Nodosa Start of enrollment: 2006 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Risk of Venous Thromboembolism with Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-enriched Rheumatoid Arthritis Patients.Christina Charles-Schoeman, Roy Fleischmann, Eduardo Mysler, Maria Greenwald, Steven R Ytterberg, Gary G Koch, Deepak L Bhatt, Cunshan Wang, Ted R Mikuls, All-Shine Ch...> ;Arthritis & Rheumatology. 2024 Mar 13
- Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician.Szekanecz, Z., Buch, M., Galloway, J., Kristensen, L., Hamar, A., Charles-Schoeman, C., Karpouzas, G., Ytterberg, S., Fleischmann, R.> ;Nature Reviews. Rheumatology. 2024 Mar 1
- 1 citationsEfficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician.Zoltán Szekanecz, Maya H Buch, Christina Charles-Schoeman, James Galloway, George A Karpouzas, Lars Erik Kristensen, Steven R Ytterberg, Attila Hamar, Roy Fleischmann> ;Nature Reviews. Rheumatology. 2024 Feb 1
- Join now to see all
Authored Content
- Arterial Lesions in Giant Cell Arteritis: A Longitudinal StudyMay 2018
- Arterial Lesions in Giant Cell Arteritis: A Longitudinal StudyMay 2018
- Arterial Lesions in Giant Cell Arteritis: A Longitudinal StudyMay 2018
Press Mentions
Xeljanz Safety Study Final Data Details the Increased Risks of Cancers and Major Adverse Cardiovascular EventsJanuary 31st, 2022- Tofacitinib's Cancer, CV Risks Outlined in Older Patients with Rheumatoid ArthritisJanuary 27th, 2022
- Tofacitinib Linked to Higher Cardiovascular, Cancer Risks Than TNF Inhibitors in RAJanuary 26th, 2022
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
